41 / 74
CARDIOVASCULAR JOURNAL OF AFRICA • Volume 30, No 2, March/April 2019
AFRICA
107
References
1.
McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong PW.
Meta-analysis: beta-blocker dose, heart rate reduction, and death in
patients with heart failure.
Ann Int Med
2009;
150
(11): 784–794.
2.
Krum H, Teerlink JR. Medical therapy for chronic heart failure.
Lancet
(Lond)
2011;
378
(9792): 713–721.
3.
Packer M, Fowler MB, Roecker EB,
et al
. Effect of carvedilol on the
morbidity of patients with severe chronic heart failure: results of the
carvedilol prospective randomized cumulative survival (COPERNICUS)
study.
Circulation
2002;
106
(17): 2194–2199.
4.
A randomized trial of beta-blockade in heart failure. The Cardiac
Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and
Committees.
Circulation
1994;
90
(4): 1765–1773.
5.
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised
trial.
Lancet
1999;
353
(9146): 9–13.
6.
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol
CR/XL Randomised Intervention Trial in Congestive Heart Failure
(MERIT-HF).
Lancet
1999;
353
(9169): 2001–2007.
7.
Ponikowski P, Voors AA, Anker SD,
et al
. 2016 ESC guidelines for the
diagnosis and treatment of acute and chronic heart failure: The Task
Force for the diagnosis and treatment of acute and chronic heart failure
of the European Society of Cardiology (ESC). Developed with the
special contribution of the Heart Failure Association (HFA) of the ESC.
Eur J Heart Fail
2016;
18
(8): 891–975.
8.
Mpe MT, Klug EQ, Silwa KS, Hitzeroth J, Smith DA. Heart Failure
Society of South Africa (HeFSSA) perspective on the European Society
of Cardiology (ESC) 2012 chronic heart failure guideline.
S Afr Med J
2013;
103
(9 Suppl 2): 660–667.
9.
Yancy CW, Jessup M, Bozkurt B,
et al
. 2017 ACC/AHA/HFSA focused
update of the 2013 ACCF/AHA Guideline for the Management of
Heart Failure: A report of the American College of Cardiology/
American Heart Association Task Force on Clinical Practice Guidelines
and the Heart Failure Society of America.
J Am Coll Cardiol
2017;
70
(6): 776–803.
10. Komajda M, Follath F, Swedberg K,
et al
. The EuroHeart Failure
Survey programme – a survey on the quality of care among patients
with heart failure in Europe. Part 2: treatment.
Eur Heart J
2003;
24
(5):
464–474.
11. Banerjee D, Stafford RS. Lack of improvement in outpatient manage-
ment of congestive heart failure in the United States.
Arch Int Med
2010;
170
(15): 1399–1400.
12. Heywood JT, Fonarow GC, Yancy CW,
et al
. Comparison of medical
therapy dosing in outpatients cared for in cardiology practices with
heart failure and reduced ejection fraction with and without device ther-
apy: report from IMPROVE HF.
Circ Heart Fail
2010;
3
(5): 596–605.
13. Ruwald AC, Gislason GH, Vinther M,
et al
. The use of guideline-
recommended beta-blocker therapy in primary prevention implantable
cardioverter defibrillator patients: insight from Danish nationwide regis-
ters.
Europace
2018;
20
(2): 301–307.
14. Cleland JG, Cohen-Solal A, Aguilar JC,
et al
. Management of heart
failure in primary care (the IMPROVEMENT of Heart Failure
Programme): an international survey.
Lancet
2002;
360
(9346): 1631–
1639.
15. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R. Heart rate
as a prognostic risk factor in patients with coronary artery disease and
left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analy-
sis of a randomised controlled trial.
Lancet
2008;
372
(9641): 817–821.
16. Swedberg K, Komajda M, Bohm M,
et al
. Effects on outcomes of heart
rate reduction by ivabradine in patients with congestive heart failure:
is there an influence of beta-blocker dose? Findings from the SHIFT
(Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial)
study.
J Am Coll Cardiol
2012;
59
(22): 1938–1945.
17. Swedberg K, Komajda M, Bohm M,
et al
. Ivabradine and outcomes in
chronic heart failure (SHIFT): a randomised placebo-controlled study.
Lancet
2010;
376
(9744): 875–885.
18. Bhatt AS, DeVore AD, DeWald TA, Swedberg K, Mentz RJ. Achieving
a maximally tolerated beta-blocker dose in heart failure patients: is there
room for improvement?
J Am Coll Cardiol
2017;
69
(20): 2542–2550.
19. Kiel RG, Deedwania P. The safety and tolerability of beta blockers in
heart failure with reduced ejection fraction: is the current underutiliza-
tion of this evidence-based therapy justified?
Exp Opin Drug Safety
2015;
14
(12): 1855–1863.
20. Barron AJ, Zaman N, Cole GD, Wensel R, Okonko DO, Francis DP.
Systematic review of genuine versus spurious side-effects of beta-block-
ers in heart failure using placebo control: recommendations for patient
information.
Int J Cardiol
2013;
168
(4): 3572–3579.
21. Callender T, Woodward M, Roth G,
et al
. Heart failure care in low- and
middle-income countries: a systematic review and meta-analysis.
PLoS
Med
2014;
11
(8): e1001699.
22. Stewart S, Wilkinson D, Hansen C,
et al
. Predominance of heart failure
in the Heart of Soweto Study cohort: emerging challenges for urban
African communities.
Circulation
2008;
118
(23): 2360–2367.
23. Szymanski PZ, Badri M, Mayosi BM. Clinical characteristics and causes
of heart failure, adherence to treatment guidelines, and mortality of
patients with acute heart failure: Experience at Groote Schuur Hospital,
Cape Town, South Africa.
S Afr Med J
2018;
108
(2): 94–98.
24. Teerlink JR. Ivabradine in heart failure – no paradigm SHIFT... yet.
Lancet
2010;
376
(9744): 847–849.
25. Deedwania PC. Ivabradine in heart failure: hope or hype?
Am J
Cardiovasc Drugs
2012;
12
(6): 357–359.